Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ Scribed by M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; E J Hathcote; H White; R T Foust; D M Jensen; E L Krawitt; H Fromm; M Black; L M Blatt; M Klein; J Lubina

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 222 KB
• Volume: 26
• Category: Article
• ISSN: 0270-9139
• DOI: 10.1002/hep.510260330

✦ Synopsis

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HCV) RNA concentration below the limit of tion compared treatment with consensus interferon (CIFN), detection by reverse-transcription polymerase chain reaction a non-natural recombinant type-1 interferon, with a standard (RT-PCR) (100 copies/mL). The beneficial effect of CIFN was regimen of recombinant interferon alfa-2b (IFN-a2b). Patients greater with the 9-mg dose than the 3-mg dose. The sustained were randomized to receive CIFN at doses of 3 mg or 9 mg, ALT and HCV RNA response rates were 20.3% and 12.1%, or 15 mg IFN-a2b (3 million units), subcutaneously three respectively, in the 9-mg CIFN cohort and 19.6% and 11.3%, times weekly for 24 weeks, followed by 24 weeks of observarespectively, in the 15-mg IFN-a2b cohort. However, patients receiving 9 mg of CIFN had a greater reduction in serum HCV RNA concentrations compared with patients receiving 15 mg Abbreviations: HCV, hepatitis C virus; RT-PCR, reverse-transcription polymerase IFN-a2b over the course of treatment (P õ .01). Similarly, chain reaction; CIFN, consensus interferon; IFN-a2b, recombinant interferon alfa-2b;

analysis of patients infected with HCV genotype 1 showed a ALT, alanine transaminase; HAI, histological activity index.